Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs. Proceeds support clinical advancement of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity.
United States
Biosight Raises $19M in Series C Funding to Support Clinical
Stage Oncology Programs. Proceeds support clinical advancement of
BST-236, a proprietary anti-metabolite enabling high-dose
chemotherapy with reduced systemic toxicity.
Mark Cohen, a Senior Partner and the Chair of
the Life Science Practice Group at Pearl Cohen, represents Biosight
in intellectual property matters.
Pearl Cohen is an international law firm with offices in Israel, the United States, and the United Kingdom. Our strength is derived from decades of legal experience and an intimate knowledge of the cutting edge technological, legal, and transactional issues facing our clients in local and cross border matters. This combination of experience and knowledge allows us to provide sound and innovative advice to clients worldwide.
